Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Anjay Rastogi_2024
VIEWPOINTS

AstraZeneca at ASN 2023: Anjay Rastogi in a Stimulating Conversation with PharmaShots

Shots: Anjay Rastogi, Professor, and Clinical Chief of Nephrology at UCLA, in an insightful conversation with PharmaShots, shares the highlights of AstraZeneca’s presentation at the American Society of Nephrology At ASN 2023, AstraZeneca shares the analysis from the ZORA study, which is a global RWE program that describes the risk of progression to end-stage kidney…
February 12, 2024

Read more

VIEWPOINTS_Andrew Menzies-Gow1_2024
VIEWPOINTS

AstraZeneca at ACR 2023: Andrew Menzies-Gow Highlights Data from the MANDARA Study

Shots:  Andrew Menzies-Gow, in a stimulating conversation with PharmaShots, shares the insights from the Phase III MANDARA study that evaluates Fasenra (benralizumab) vs. mepolizumab for patients with relapsing or refractory EGPA  Five out of the 18 abstracts presented by AstraZeneca at ACR were from the MANDARA study. Apart from the positive endpoints of the MANDARA…
February 6, 2024

Read more

VIEWPOINTS_Micki Hultquist_2024
VIEWPOINTS

AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo

Shots:  AstraZeneca at ACR 2023 presented 18 abstracts from its respiratory and immunology pipelines  Micki Hultquist in a stimulating conversation with PharmaShots sheds light on Saphnelo, AstraZeneca’s first-in-class biologic treatment for systemic lupus erythematosus (SLE)  The post-hoc analysis of the TULIP P-III program reveals that the patients showcased more frequent and sustained remission as compared…
February 5, 2024

Read more

VIEWPOINTS_Helen Yeh1_Naim Shehadeh2_2023
VIEWPOINTS

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Shots: At the EASD, AZ announced positive results from the T2NOW P-III study that evaluated the efficacy and safety of Forxiga as an add-on treatment in children and adolescents with T2D receiving metformin, insulin, or both Helen Yeh, VP, CVRM Therapy Area Biopharmaceuticals Medical at AstraZeneca, and Naim Shehadeh, Professor of Endocrinology, Rambam Health Care…
December 11, 2023

Read more

VIEWPOINTS_Andrew Menzies-Gow2_2024
VIEWPOINTS

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Shots  While sharing the details on Fasenra, Andrew highlights the unmet medical need in the healthcare sector as there’s only one approved treatment for EGPA  With mepolizumab as the comparator drug for the trial, Andrew shares the positive results in achieving remission rates. Andrew sheds light on the unique mechanism of benralizumab that directly targets…
December 4, 2023

Read more

Load more